R141
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 82
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- PANCREAS_BETA_CELLS+0.240
- BILE_ACID_METABOLISM+0.160
- SPERMATOGENESIS+0.150
- ANDROGEN_RESPONSE+0.120
- PI3K_AKT_MTOR_SIGNALING+0.080
- UV_RESPONSE_DN+0.080
- XENOBIOTIC_METABOLISM+0.060
- HEME_METABOLISM+0.030
- FATTY_ACID_METABOLISM+0.020
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MYC_TARGETS_V2-0.450
- ANGIOGENESIS-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- APICAL_JUNCTION-0.350
- INTERFERON_ALPHA_RESPONSE-0.320
- MYOGENESIS-0.320
- E2F_TARGETS-0.300
- GLYCOLYSIS-0.280
- NOTCH_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2993 | Med | Medulloblastoma | 0.856 |
| 2 | MDT-AP-2991 | Med | Medulloblastoma | 0.833 |
| 3 | MDT-AP-0441 | Med | Medulloblastoma | 0.831 |
| 4 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.830 |
| 5 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.829 |
| 6 | BS_ME3HKN2C | Ganglioglioma | — | 0.828 |
| 7 | SRR657754 | GTEX | — | 0.825 |
| 8 | SRR975556 | — | — | 0.824 |
| 9 | MNG39 | — | — | 0.818 |
| 10 | MBCProject_1509_T1_RNA | — | B | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |